- Home
- GLBZ vs TLPH Comparison
GLBZ vs TLPH Comparison
Compare GLBZ & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- TLPH
- Stock Information
- Founded
- GLBZ 1949
- TLPH 2005
- Country
- GLBZ United States
- TLPH United States
- Employees
- GLBZ N/A
- TLPH N/A
- Industry
- GLBZ Major Banks
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- TLPH Health Care
- Exchange
- GLBZ Nasdaq
- TLPH Nasdaq
- Market Cap
- GLBZ 12.4M
- TLPH 11.1M
- IPO Year
- GLBZ N/A
- TLPH 2011
- Fundamental
- Price
- GLBZ N/A
- TLPH $1.15
- Analyst Decision
- GLBZ
- TLPH Strong Buy
- Analyst Count
- GLBZ 0
- TLPH 1
- Target Price
- GLBZ N/A
- TLPH $6.00
- AVG Volume (30 Days)
- GLBZ 5.0K
- TLPH 395.8K
- Earning Date
- GLBZ 10-30-2025
- TLPH 11-12-2025
- Dividend Yield
- GLBZ N/A
- TLPH N/A
- EPS Growth
- GLBZ N/A
- TLPH N/A
- EPS
- GLBZ 0.01
- TLPH N/A
- Revenue
- GLBZ $12,483,000.00
- TLPH $27,000.00
- Revenue This Year
- GLBZ N/A
- TLPH N/A
- Revenue Next Year
- GLBZ N/A
- TLPH $14,533.26
- P/E Ratio
- GLBZ $458.79
- TLPH N/A
- Revenue Growth
- GLBZ 8.71
- TLPH N/A
- 52 Week Low
- GLBZ $3.89
- TLPH $0.38
- 52 Week High
- GLBZ $6.99
- TLPH $1.45
- Technical
- Relative Strength Index (RSI)
- GLBZ 49.46
- TLPH 65.27
- Support Level
- GLBZ $4.70
- TLPH $0.86
- Resistance Level
- GLBZ $4.79
- TLPH $1.45
- Average True Range (ATR)
- GLBZ 0.10
- TLPH 0.12
- MACD
- GLBZ -0.01
- TLPH 0.01
- Stochastic Oscillator
- GLBZ 52.27
- TLPH 49.32
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.